Why Skills-First Leadership Is Replacing the Ivy League Playbook in the C-Suite
05/23/2025
No Comments
The old prestige pyramid—where Ivy League degrees and blue-chip consulting backgrounds paved the way to the CEO seat—is cracking.
Novartis has confirmed that it will spin off its Sandoz generics division on October 4, 2023. The spin-off will create two independent companies: Novartis, which will focus on innovative medicines, and Sandoz, which will focus on generics and biosimilars.
The spin-off is part of Novartis’s strategy to focus on its core businesses and to create two more agile and competitive companies. Novartis has said it expects the spin-off to be completed in the first half 2023.
The spin-off of Sandoz will be a major event in the pharmaceutical industry. Sandoz is one of the world’s largest generics companies, and Novartis is one of the world’s largest pharmaceutical companies. The spin-off will create two new independent companies with strong positions in their respective markets.
Novartis has said it expects the spin-off to create value for shareholders and patients. Novartis shareholders will receive one share of Sandoz for every five shares of Novartis that they own. Sandoz will be listed on the SIX Swiss Exchange, with an American Depositary Receipt (ADR) program in the US.
The spin-off of Sandoz is a significant development for the global healthcare industry. It is a sign that Novartis is committed to its core businesses and creating a more competitive and innovative pharmaceutical industry.
The spin-off of Sandoz is also a positive development for patients. It is likely to lead to increased competition in the generics market, which could lead to lower prices for patients.
It will be interesting to see how the two new companies, Novartis and Sandoz, perform in the future. The spin-off may be a success for both companies and patients.
The old prestige pyramid—where Ivy League degrees and blue-chip consulting backgrounds paved the way to the CEO seat—is cracking.
Loud leaders once ruled the boardroom. Charisma was currency. Big talk drove big valuations.
But the CEOs who make history in downturns aren’t the ones with the deepest cuts
Companies invest millions in leadership development, yet many of their best executives leave within a few years. Why?
The most successful business leaders don’t just identify gaps in the market; they anticipate future needs before anyone else.
With technological advancements, shifting consumer expectations, and global interconnectedness, the role of business leaders
Maushum Basu is a visionary leader who inspires his team with a clear, compelling purpose. Unafraid to take calculated risks, he understands that growth often stems from change and innovation. His deep commitment to both Airia Brands, Inc.
When speaking with Martin Paquette, one thing is immediately apparent: he’s honest. His transparency is refreshing. While many shy away from such vulnerability, Paquette sees it as a force to reckon with. The incredible emotional intelligence speaks to years of looking within—it’s also what allows him to acknowledge his mistakes gracefully and use them as opportunities to innovate.
Marina Charriere, CEO of Star Drug Testing Services, Star Drug Testing Services (Windsor Park), and First Defence Face Masks go hand in hand. Star is a drug and alcohol testing facility, and First D F M is a face mask company.
Lejjy Gafour, CEO, CULT Food Science Corp. Lejjy is a self-taught entrepreneur and experienced company operator who made his start creating opportunities at the young age of 14, and he has been working, leading, and building businesses ever since.
Leave us a message
Subscribe
Fill the form our team will contact you
Advertise with us
Fill the form our team will contact you
